We’re excited to introduce our four-part white paper series exploring how microsatellite instability (MSI) is reshaping the landscape of precision oncology — from molecular insights to clinical decision-making.
📗 Part 1: Understanding MSI in Cancer
A clear overview of what MSI is, why it matters, and how this biomarker reveals crucial information about tumor biology and DNA repair mechanisms.
🔬 Part 2: Diagnostics and Detection (coming soon)
A look into evolving MSI testing technologies — from PCR and IHC to NGS — and how standardization impacts reliability and interpretation.
💊 Part 3: Therapeutic Implications (coming soon)
Exploring how MSI guides immunotherapy selection and influences patient outcomes across multiple cancer types.
🧬 Part 4: Hereditary Insights (coming soon)
Connecting MSI to Lynch syndrome and hereditary cancer predisposition — and what this means for screening and prevention.
📘 Read Part 1 now:
